1. Medtech Insight
  2. >>Business

Illumina Remains Committed To Grail Merger Despite Regulators' Doubts

 
• By Reed Miller

Illumina insists its proposed $8bn acquisition of Grail, the developer of the Galleri multi-cancer test, would be “pro-competitive.” But antitrust regulators in the US government and European Commission suspect the deal would reduce competition and innovation in the future genomic diagnostics market.

Antitrust law - Image

Illumina, Inc.'s proposed acquisition of Grail Inc. faces intense regulatory scrutiny in Europe and the US but, the companies are still planning to complete the $8bn deal by the end of the year.

Illumina announced plans to Grail for about $8bn in September 2020. Illumina originally spun-off Grail in 2016, but Illumina now wants to reacquire the Silicon Valley company to add Grail’s Galleri multi-cancer detection blood test to its existing line of genomic sequencing products

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Synchron And Apple Team Up To Use ‘Mind-Thought Connection’ To Control iPhones, iPads

 
• By Marion Webb

Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Danaher Faces $350M Tariff Hit, But Says It’s Ready To Absorb The Blow

 
• By Shubham Singh

Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.